{"public_id":"co_0f1a025a933007da2d52362608a20f12","status":"active","merged_into_public_id":null,"resolved_public_id":"co_0f1a025a933007da2d52362608a20f12","name":"clinical anticancer potential","description":"The potential of a compound to be developed for cancer treatment in clinical settings.","aliases":[],"types":["therapeutic potential"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":4228513,"title":"The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53","citation_count":40,"url":"https://sah.borca.ai/papers/4228513"}],"claims":[{"public_id":"cl_53500fe99876b28f71dbb327b54c2218","text":"HO-3867 is a p53 mutant-reactivating drug with high clinical anticancer potential.","corpus_id":4228513,"url":"https://sah.borca.ai/claims/cl_53500fe99876b28f71dbb327b54c2218"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_0f1a025a933007da2d52362608a20f12","url":"https://sah.borca.ai/concepts/co_0f1a025a933007da2d52362608a20f12"}